Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987.

scientific article published in January 1989

Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. is …
instance of (P31):
scholarly articleQ13442814

External links are
P698PubMed publication ID2462943

P2093author name stringThomas J
Carde P
Hayat M
Tubiana M
Henry-Amar M
Tanguy A
Noordijk EM
Van der Schueren E
Burgers JM
Meerwaldt JH
P433issue1
P407language of work or nameEnglishQ1860
P304page(s)47-56
P577publication date1989-01-01
P1433published inBloodQ885070
P1476titleToward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987.
P478volume73

Reverse relations

cites work (P2860)
Q71952238A 37-year-old man with cholestatic jaundice and a prior history of Hodgkin's disease
Q40575600ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II.
Q28078115ACR Appropriateness Criteria® Recurrent Hodgkin Lymphoma
Q93134714Assessment of the Neutrophil-Lymphocyte Ratio in Classic Hodgkin Lymphoma Patients
Q35606768Changing patterns in the clinical pathological features of hodgkin lymphoma: a report from debrecen, hungary
Q51050643Clinical characteristics and prognostic factors in Chinese patients with Hodgkin's lymphoma.
Q93261031Current considerations in AYA Hodgkin lymphoma
Q35117413Current therapies in Hodgkin's disease
Q46666583Early prediction of response to therapy: the clinical implications in Hodgkin's and non-Hodgkin's lymphoma
Q36722986Early stage Hodgkin's disease in adults: which is the correct treatment?
Q48346165Excess mortality among 10-year survivors of classical Hodgkin lymphoma in adolescents and young adults.
Q35822699Hodgkin's disease--I: Identification and classification
Q35662615Hodgkin's lymphoma. II: Treatment and delayed morbidity
Q71141093Is laparoscopic splenectomy appropriate for the management of hematologic and oncologic diseases?
Q31153389Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL)-clinicopathological features based on the data of two Hungarian lymphoma centres
Q93789904PANEL DISCUSSION: MYELOMA &LYMPHOMA: Tuesday 12 October 2004, 14:00–16:00
Q34235785Role of Radiotherapy in Modern Treatment of Hodgkin's Lymphoma
Q39976522Role of imaging to choose treatment
Q35977542Serum lactate dehydrogenase level as a prognostic factor in Hodgkin's disease.
Q34486551Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience
Q26781731Systematic review and meta-analysis on the prognostic value of complete remission status at FDG-PET in Hodgkin lymphoma after completion of first-line therapy
Q54983414The role of primary lymph node sites in survival and mortality prediction in Hodgkin lymphoma: a SEER population-based retrospective study.
Q54304195The scientific bases of cancer management: at the interface between fundamental research and clinical practice.
Q35667908Variables affecting survival after second primary lung cancer: A population-based study of 187 Hodgkin's lymphoma patients